GeoVax Labs, Inc. — Q2 2018 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2018. Unaudited results. GeoVax is a clinical-stage biotechnology company developing vaccines for infectious diseases and cancer using its MVA-VLP platform. It has not generated product sales and expects no product revenue for several years.
Financial highlights
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Grant and collaboration revenue | $93,265 | $352,137 | $314,564 | $647,872 |
| Research and development | $372,202 | $518,098 | $859,196 | $1,069,893 |
| General and administrative | $359,197 | $352,191 | $716,425 | $644,858 |
| Net loss | $637,043 | $516,881 | $1,258,856 | $1,065,222 |
| Operating cash used | Not provided for quarter | Not provided for quarter | $761,758 | $761,250 |
- At June 30, cash and equivalents were $190,969, down from $312,727 at December 31, 2017. Total assets were $371,380.
- Current liabilities were $1,068,262; working capital deficit was $729,113. Total liabilities were $1,114,094, including a $50,000 GRA note payable. The note bears 5% interest, with principal payments beginning in 2019.
- Stockholders’ deficiency was $742,714. No meaningful product gross margin is reported; revenue consists of grants and collaborations.
- Financing provided $640,000 in the first half: $590,000 net proceeds from Series E preferred stock and $50,000 from the GRA note. Cash declined by $121,758.
Changes versus prior comparable periods
- Revenue declined 74% in Q2 and 51% for the first half, reflecting lower grant-related activity and the absence of the $95,000 AGT collaboration fee recognized in Q2 2017. Q2 grant and collaboration revenue was $93,265; first-half revenue included $5,000 from the USNRL collaboration.
- First-half R&D expense fell about 20%, while G&A rose about 11%. Despite lower total operating expenses, first-half net loss increased by about 18% as lower revenue more than offset expense reductions.
- Operating cash use was nearly unchanged year over year. First-half 2018 financing proceeds were lower than in 2017.
- During the first half, 795 Series D preferred shares converted into 53 million common shares; the company also issued 5 million common shares for financial advisory services. Common shares outstanding were 164.7 million at June 30 and 169.7 million as of August 7.
Outlook, risks and notable items
- Going concern: Management estimated existing cash and government funding would support planned operations only to mid-September 2018. The filing states there is substantial doubt about the company’s ability to continue as a going concern beyond that point; management’s plans to raise capital do not alleviate that doubt. Funding may not be available on favorable terms or at all.
- The company is pursuing additional grants, clinical-trial support and equity financing. Failure to obtain capital could require delaying, reducing or eliminating development programs and cutting administrative costs.
- Accrued management salaries and director fees totaled $949,312 and were being deferred to conserve cash. Management salary deferrals were expected to continue at approximately $29,100 per month until a significant financing event.
- Approved grant funds available at June 30 totaled $771,951. The company said NIAID was funding ongoing HIV clinical work and expected a Phase 1 study of additional protein boosts to begin in the second half of 2018; a larger Phase 2b trial could follow, subject to study results and support.
- Commitments totaled approximately $326,000, comprising lease payments and firm research purchase commitments; approximately $248,000 of purchase commitments were expected to be reimbursable under existing grants. The office and laboratory lease expires December 31, 2018, with extension options.
- Key risks include lengthy and uncertain clinical development and regulatory approval, competition, continued operating losses, financing availability and potential dilution. Series E preferred stock has a conversion-price adjustment feature. The filing reports no material change to previously disclosed risk factors and no legal proceedings.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Investor verification points
- Confirm subsequent financing, grant awards and cash runway, given the mid-September 2018 funding estimate and going-concern warning.
- Track actual collection and use of the $771,951 in approved grant funds and whether related research commitments are reimbursed.
- Review the terms and potential dilution from Series E preferred stock, preferred conversions, advisory shares and other potentially dilutive securities.
- Monitor deferred executive and director compensation, accrued liabilities, and the timing of any repayment.
- Verify progress and funding for the planned HIV studies and other vaccine programs; development timelines and trial outcomes remain uncertain.